Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer

This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Treatment Options for mCRPC

5 FDA-Approved Therapies Can Be Used in Any Sequence

Case 1: 75-Year-Old Caucasian Man

Case 1 (cont)

Case 1: Patient Bone Scans

Pattern of Disease in mCRPC Over Time

Radium-223

ALSYMPCA: Randomized, Phase 3 Trial of Radium-223 in Symptomatic mCRPC

ALSYMPCA Subgroup Analysis by Prior Docetaxel Therapy

Abiraterone in Chemotherapy-Naive mCRPC COU-AA-302 Trial

Enzalutamide in Chemotherapy-Naive mCRPC PREVAIL Trial

Phase 3b Expanded Access Trial of Radium-223

Radium-223 Phase 3b Trial: Concomitant Use of Abiraterone or Enzalutamide

Ongoing Combination Therapy Trials

OS in ALSYMPCA by Bisphosphonate Use

OS in ALSYMPCA by Baseline Opioid Use

Case 1 Wrap-Up: Patient's PSA Response to First-Line Radium-223

Patient's Responses on PET Scan and Functional MRI

Case 2: 59-Year-Old Caucasian Man

Case 2: Bone Scan, September 2015

Case 2 (cont)

Case 2: Bone Scan, January 2017

Case 2: Treatment Options

Case 2: Conclusion

LATITUDE Trial: Early Abiraterone in Newly Diagnosed mHNPC

STAMPEDE Trial: Early Abiraterone in Newly Diagnosed mHNPC

ARASENS: Randomized, Double-Blind, Phase 3 Trial of ODM-201* in mHSPC

Tumor Genetic Sequencing

AR-V7 Status and Resistance to Enzalutamide and Abiraterone

New Approaches and Future Directions

Multidisciplinary Approach to mPC: Perspective of the Community Urologist

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)